Bayer Initiates Phase 2 Study for Alport Syndrome Treatment with Evotec

Evotec SE and Bayer AG have announced the start of a Phase 2 clinical trial evaluating a new treatment for Alport syndrome. This study will assess the efficacy and safety of BAY 3401016, a monoclonal antibody targeting the protein Semaphorin-3A. Alport syndrome is a rare genetic kidney disease that leads to progressive kidney damage, often resulting in end-stage renal disease and hearing loss.

The trial, named ASSESS, is a randomized, double-blind, placebo-controlled study targeting participants aged 18 to 45. A milestone payment to Evotec is expected with the first patient's dosing in early 2026. Evotec and Bayer have collaborated on this program since 2016, aiming to delay the progression of Alport syndrome and improve the quality of life for affected individuals.